NCT02536248View on ClinicalTrials.gov

Sitagliptin Therapy and Kinetics of Inflammatory Markers

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

October 31, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin

Sitagliptin 100 mg/d for 6 weeks

DRUG

Placebo

Placebo for 6 weeks

Trial Locations (1)

G1V 0A6

Laval University, Québec

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Laval University

OTHER

NCT02536248 - Sitagliptin Therapy and Kinetics of Inflammatory Markers | Biotech Hunter | Biotech Hunter